Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)
Clinical trial NCT01749514 · COMPLETED
Trial details
- NCT number
- NCT01749514
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2013-01-21
- Primary completion
- 2018-10-22
- Enrollment
- 116
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.